{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-007473","form_type":"8-K","ticker":"PAVM","cik":"0001624326","company_name":"PAVmed Inc.","filed_at":"2023-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.900518+00:00","generated_at":"2026-06-18T04:29:02.034859+00:00","sec_items":["1.01","3.03","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"PAVMED's Lucid Diagnostics raises $13.625M via Series A Preferred private placement","bullets":["Issued 13,625 shares of Series A Convertible Preferred at $1,000/share; gross proceeds $13.625M.","Closing occurred on March 7, 2023; private placement with accredited investors.","Certificate of Designation filed with Delaware establishing Series A Preferred terms.","Further details incorporated by reference to Lucid Diagnostics' Form 8-K filed March 13, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-007473","json":"https://secwatch.observer/filing/0001493152-23-007473.json","markdown":"https://secwatch.observer/filing/0001493152-23-007473.md","text":"https://secwatch.observer/filing/0001493152-23-007473.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1624326/000149315223007473/0001493152-23-007473-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1624326/000149315223007473/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T04:29:02.034859+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"281ff9311574996a42586ea450a427e0610441b0","claim":"PAVmed Inc. entered into Subscription Agreement with certain accredited investors valued at $13.625 million (effective 2023-03-07).","evidence_excerpt":"On March 7, 2023, Lucid Diagnostics Inc. (the “ Lucid Diagnostics ” or the “ Company ”) entered into subscription agreements (each, a “ Subscription Agreement ”) with certain accredited investors for the sale of 13,625 shares of newly designated Series A Convertible Preferred Stock, par value $0.001 per share (the “ Series A Preferred Stock ”), at a purchase price of $1,000 per share, for aggregate gross proceeds to the Company of $13.625 million, in a private placement (the “ Preferred Offering ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1624326/000149315223007473/0001493152-23-007473-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain accredited investors"},{"label":"Value","value":"$13.625 million"},{"label":"Effective","value":"2023-03-07"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}